A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms BREEZE AD-1
- Sponsors Eli Lilly; Eli Lilly Japan
- 02 Nov 2018 Planned primary completion date changed from 4 Dec 2018 to 18 Jul 2019.
- 01 Oct 2018 Planned primary completion date changed from 18 Jul 2019 to 4 Dec 2018.
- 21 Aug 2018 Planned End Date changed from 1 Jan 2019 to 15 Aug 2019.